Cancers | Notable Papers in the Section "Cancer Drug Development"

As all the articles published in Cancers (ISSN: 2072-6694) are open access, you have free and unlimited access to the full text of all articles. We welcome you to read our notable papers in the Section “Cancer Drug Development”, which are listed below.

1. “Targeting Esophageal Squamous Cell Carcinoma by Combining Copper Ionophore Disulfiram and JMJD3/UTX Inhibitor GSK J4”
by Canlin Yang, Fei Li, Yuanyuan Ren, Qianqian Zhang, Bo Jiao, Jianming Zhang and Junxing Huang
Cancers 2023, 15(22), 5347; https://doi.org/10.3390/cancers15225347
Available online: https://www.mdpi.com/2072-6694/15/22/5347

2. “Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice”
by Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman and Hope S. Rugo
Cancers 2023, 15(21), 5268; https://doi.org/10.3390/cancers15215268
Available online: https://www.mdpi.com/2072-6694/15/21/5268

3. “A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)”
by Takayuki Nagasawa, Tadahiro Shoji, Eriko Takatori, Yoshitaka Kaido, Masahiro Kagabu, Dai Shimizu, Tatsuhiko Shigeto, Tsukasa Baba, Toru Sugiyama and Yoshihito Yokoyama
Cancers 2023, 15(21), 5201; https://doi.org/10.3390/cancers15215201
Available online: https://www.mdpi.com/2072-6694/15/21/5201

4. “Towards Cancer Nanoradiopharmaceuticals—Radioisotope Nanocarrier System for Prostate Cancer Theranostics Based on Radiation-Synthesized Polymer Nanogels”
by Beata Paulina Rurarz, Kinga Anna Urbanek, Urszula Karczmarczyk, Joanna Raczkowska, Dominika Ewa Habrowska-Górczyńska, Marta Justyna Kozieł, Karolina Kowalska, Sławomir Kadłubowski, Agnieszka Sawicka, Michał Maurin et al.
Cancers 2023, 15(23), 5646; https://doi.org/10.3390/cancers15235646
Available online: https://www.mdpi.com/2072-6694/15/23/5646

5. “Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response”
by Vishnupriyadevi Parvathareddy, Umut Selamet, Aditi A. Sen, Omar Mamlouk, Juhee Song, Valda D. Page, Maen Abdelrahim, Adi Diab, Noha Abdel-Wahab and Ala Abudayyeh
Cancers 2023, 15(21), 5181; https://doi.org/10.3390/cancers15215181
Available online: https://www.mdpi.com/2072-6694/15/21/5181

6. “Discovery, Structure–Activity Relationship and In Vitro Anticancer Activity of Small-Molecule Inhibitors of the Protein–Protein Interactions between AF9/ENL and AF4 or DOT1L”
by Xin Li, Xiaowei Wu, Shenyou Nie, Jidong Zhao, Yuan Yao, Fangrui Wu, Chandra Bhushan Mishra, Md Ashraf-Uz-Zaman, Bala Krishna Moku and Yongcheng Song
Cancers 2023, 15(21), 5283; https://doi.org/10.3390/cancers15215283
Available online: https://www.mdpi.com/2072-6694/15/21/5283

7. “Photodynamic Therapy with an Association of Methylene Blue and Toluidine Blue Promoted a Synergic Effect against Oral Squamous Cell Carcinoma”
by Évilin Rocha, Larissa Bomfim, Sérgio Junior, Gustavo Santos, Cássio Meira and Milena Soares
Cancers 2023, 15(23), 5509; https://doi.org/10.3390/cancers15235509
Available online: https://www.mdpi.com/2072-6694/15/23/5509

8. “Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest”
by Boaz Nachmias, Svetlana Krichevsky, Moshe E. Gatt, Noa Gross Even-Zohar, Adir Shaulov, Arnon Haran, Shlomzion Aumann and Vladimir Vainstein
Cancers 2023, 15(22), 5360; https://doi.org/10.3390/cancers15225360
Available online: https://www.mdpi.com/2072-6694/15/22/5360

9. “Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal”
by Mariusz L. Hartman, Paulina Koziej, Katarzyna Kluszczyńska and Małgorzata Czyz
Cancers 2023, 15(19), 4799; https://doi.org/10.3390/cancers15194799
Available online: https://www.mdpi.com/2072-6694/15/19/4799

10. “Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study”
by Ioannis Petrakis, Christos Kontogiorgis, Evangelia Nena, Sosana Delimpasi, Natasa E. Loutsidi, Emmanouil Spanoudakis, Stergios Intzes, Christina Misidou, Marianthi Symeonidou, Nikolaos Giannakoulas et al.
Cancers 2023, 15(24), 5846; https://doi.org/10.3390/cancers15245846
Available online: https://www.mdpi.com/2072-6694/15/24/5846

You are invited to view and submit relevant papers to the journal Cancers.

Cancers Editorial Office